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In this study, we scanned multiple published databases of gene expression in vivo of M. tuberculosis at different
phases of infection in animals and humans, to select 38 proteins that are highly expressed in the active, latent
and reactivation phases. The selected proteins were predicted for T and B epitopes. For each proteins, the
regions containing T and B epitopes were selected at the same time to look for identical epitopes on M. smegmatis
based on sequence alignments. Preliminary studies of humoral immunogenicity and cross-reactivity with M.
tuberculosis in mice using two M. smegmatis-derived experimental vaccines were carried out, demonstrating the
immunogenicity of M. smegmatis proteoliposomes and the recognition of M. tuberculosis proteins by the sera of
animals immunized with this vaccine candidate. The conjunction of in silico and in vivo studies suggested the
potential for future evaluation of M. smegmatis as vaccine candidate against tuberculosis using different strategies.
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Introduction
Mycobacterium tuberculosis, the main agent of tuberculosis
(TB) in humans caused 9.2 million new cases and 1.7 million
deaths in 2006. It is estimated that up to one third of the
world’s population has been infected with M. tuberculosis
(1). The current vaccine, Mycobacterium bovis Bacillus
Calmette–Guerin (BCG) is the most widely used in humans.
However, the uncertain efficacy of BCG vaccine in the
prevention of pulmonary TB in adults, and the emergence of
extensively drug resistant M. tuberculosis strains have further
enhanced the sense of urgency in the development of new
TB vaccines (2). With the complete genome sequence of
M. tuberculosis and the advances in the sequencing of BCG
and other mycobacteria, an enormous flow of valuable
information has been made available for new vaccine
strategies (2, 3).
Vaccine design is highly suited to the application of in silico
techniques, for both discovery and development of new and
existing vaccines (3). Bioinformatic tools allow selecting
regions of microbial genomes that trigger immune responses
against vaccine components. In order to give a bigger impact
to the bioinformatic studies it is important to take into
consideration the data obtained from studies of gene
expression in vivo of M. tuberculosis. This combination will
focus the studies on a smaller group of relevant antigens to
be used in vaccine development (3).
The fast-growing and nonpathogenic soil bacterium
Mycobacterium smegmatis which shares many features
and identical genomic sequences with the pathogenic
M. tuberculosis (4) is a potential candidate for developing
new TB vaccines. The use of M. smegmatis is expected
to have more advantages for TB vaccine development,
feasible for research in normal laboratories, saving time
and cost. With the aim to evaluate the antigenic similarity
between M. smegmatis and M. tuberculosis, a combination
of in silico and in vivo studies was carried out.
Materials and methods
Identification and selection of in vivo expressed
genes of M. tuberculosis
A search using the Internet Google Search Tool to find articles
reporting in vivo studies of M. tuberculosis gene expression
in humans and animals was carried out. The genes that are
highly expressed in common in humans and animals at all
stages of infection: activation, latency and reactivation were
selected for epitope prediction.
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Epitope prediction
The amino acid sequences and the features of the selected
genes were obtained from the Reference Sequence (RefSeq)
database (http://www.ncbi.nlm.nih.gov/RefSeq/) at the
National Center for Biotechnology Information (NCBI) (http:/
/www.ncbi.nlm.nih.gov/).
T-cell epitope prediction
HLAPred server was used for prediction of T-cell epitopes in
this study. The program is developed by Bioinformatics Centre
Institute of Microbial Technology, India (http://
www.imtech.res.in/ raghava/hlapred/). All the alleles from the
list of 36 HLA class I and 51 HLA class II were selected for
the prediction.
B-cell epitope prediction
Two servers, Bcepred and ABCpred, were combined for linear
B-cell epitope prediction. Bcepred server is accessible at
http://www.imtech.res.in/raghava/bcepred/ and ABCpred web
server is accessible at www.imtech.res.in/raghava/abcpred/.
For Bcepred server we combined of 7 physico-chemical
properties of amino acids (hydrophilicity, flexibility,
accessibility, polarity, exposed surface and turns and
antigenic propensity). For ABCpred server we predicted B
epitope length of 16 amino acids.
Searching for identical epitopes on M. smegmatis
The regions in the sequences of the 38 selected proteins of
M. tuberculosis containing T and B epitopes at the same time
were used to identify the identical epitopes on M. smegmatis
genome using BLAST.
(http://www.ncbi.nlm.nih.gov//genomes/geblast.cgi?gi=20087)
Prediction of subcellular localization of proteins
from M. tuberculosis and M. smegmatis
The subcellular localization of the selected M. tuberculosis
proteins were defined according to the report of the
identification and localization of 1044 M. tuberculosis proteins
using two-dimensional, capillary high-performance liquid
chromatography coupled with mass spectrometry (2DLC/MS)
method (5).
The amino acid sequences of M. smegmatis proteins
containing identical epitopes with M. tuberculosis and
their features were obtained from the Reference Sequence
(RefSeq) database (http://www.ncbi.nlm.nih.gov/RefSeq) at
NCBI. To determine the subcellular location of the proteins of
M. smegmatis and the proteins of M. tuberculosis that were
not in the first list of 1044 proteins, we used TBpred server.
TBpred is freely available at http://www.imtech.res.in/raghava/
tbpred/
Evaluation of the immunogenicity and the cross-
reactivity with M. tuberculosis on mice
immunized with M. smegmatis vaccine
candidates
M. smegmatis culture
Lyophilized cells of M. smegmatis from Molecular Biology
Laboratory, Finlay Institute, were used in this study. The cells
were grown at 37 °C, shaked at 200 rpm in culture broth
medium containing glycerol 0.05 % and 0.05 % tween 80.
Preparing proteoliposomes from M. smegmatis
Biomass of M. smegmatis was obtained from centrifugation
of the broth culture at 17700 x g (centrifuge J2-21, Beckman,
EUA) during 1 hour, at 4 oC. The biomass was suspended in
buffer (10-30 mM Tris, 2-10mM EDTA, pH 7-8.5) and washed
twice. After suspension of the pellet in the same buffer, sodium
deoxycholate (5-15%) was added with the ratio 0.1-0.25 mL/g
biomass. After centrifugation with the same conditions, the
supernatant was ultra-centrifugated at 50000-70000 x g
(centrifuge L7-65 Beckman, EUA) for 2-8 hours at 4 °C . The
sediment was resuspended in the buffer and filtrated with
Sartorius Minisart-plus filter 0.45-0,2 µm.
Mice immunization
Fifteen female Balb/c mice of 6-8 weeks of age (16-18 g
weight) obtained from the National Center of Laboratory
Animals (CENPALAB), La Habana, Cuba, were used. The
animals were housed in appropriate biological containment
facilities at Animal Laboratory, Finlay Institute. All the
experimental procedures were carried out following the guide
for the use of Laboratory Animals (EEC Council Directive,
1987). The animals were distributed into 3 experimental
groups (n=5): (i) negative control group consisted of mice
receiving one dose at T0 of PBS; (ii) mice receiving two doses
of proteoliposomes of M. smegmatis (50 µg/dose/mouse) in
Freund’s incomplete adjuvant at T0 and T21 (day 21 after the
first immunization); (iii) mice immunized by a single dose at
T0 with live cells of M. smegmatis (1 x 10
6 cfu).
Mice of all groups were injected via the subcutaneous route.
42 days after the first inoculum, the blood of mice of all groups
was collected and centrifugated to obtain the sera.
ELISA to determine antibody responses
Flat bottomed polystyrene ELISA plates (MaxiSorp, Nunc) were
coated (100 µL/well) 16 hours at 4 °C  with 5 µg/mL M. smegmatis
proteoliposomes, 5 µg/mL whole cell lysate of M. tuberculosis.
106 cfu/mL of live-cell M. smegmatis were coated 16 hours at
37 °C. The antigens were dissolved in the coating buffer
(Carbonate/Bicarbonate 0,1 M, pH 9,6) and added to the
plates. The plates were blocked with blocking buffer (PBS
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with 3% skim milk) for 1 hour at 37 oC. Serum  samples were
diluted 1/50 with 1% skim milk (w/v) in PBS (NaCl 137 mM,
KCl 2.7 mM, Na2HPO4.7H2O, KH2PO4 1.4 mM, pH 7.4 and were
added (100 µL/well) into each well. The samples were
assayed in duplicate and were incubated 1 hour at 37 °C .
The plates were incubated for 1 hour at 37 °C with the
peroxidase-conjugated secondary antibody (affinity-purified
anti-mouse IgG; Sigma, cod A-4416) in a dilution of 1/1000
(100 µL/well). The reaction was developed with the solution
of o-phenylenediamine (OPD; Sigma): 5 mg of OPD in 12.5
mL of sodium citrate buffer 0.1M, pH 5, H2O2 5 µL (100 ìL/
well). The reaction was stopped with 50 µL/well of H2SO4 2N
after 20-30 minutes incubation with OPD solution. The
absorbance was recorded at 492 nm with an ELISA plate
reader (Multiskan Multisoft). Each experiment was carried
out twice.
Statistical analysis
ELISA results were analyzed using ANOVA to determine
significant differences among the groups at the 95%
confidence level. Multiple range test were used to determine
pairs with significant differences.
Results
Identification and selection of in-vivo highly
expressed genes of M. tuberculosis
In this study, we analyzed published articles of gene
expression of M. tuberculosis during different phases of
infection in animals and humans (6-24): from humans, animals
(mainly on mice and rabbits) and from both humans and mice.
These studies were directed to identify M. tuberculosis genes
of responsible for the adaptation and evasion from the host
immune responses and drugs as well as for the reactivation
of infection and invasion of the bacteria. The expression
profile under different conditions of 3924 genes from M.
tuberculosis during different stages of infection in different
hosts was identified (11, 12, 16-19).
A total of 38 M. tuberculosis genes that were reported
significantly up-regulated at the active, latent and reactivation
phases were selected from the whole genome. The amino
acid sequences obtained and the features of the selected
genes from the Reference Sequence (RefSeq) database the
subcellular localization of the corresponding proteins were
identified.
Subcellular localization prediction provides important
information about a protein that allows making inferences
regarding to the protein’s function, to annotate genomes, and
particularly in the case of bacterial pathogens to identify
potential diagnostic, drug and vaccine targets. The
distribution of subcellular location of 38 selected proteins
are shown in Figure 1.
Searching for identical epitopes on M.
smegmatis
The regions containing T and B epitopes at the same time of
38 selected M. tuberculosis proteins were the bases to look
for identical epitopes on M. smegmatis. In these regions, 1367 T-
cell epitopes and 140 B-cell epitopes were identified on
M. tuberculosis. Using BLAST a search was made on the
whole genome of M. smegmatis. 68 identical T-cell epitopes
and 11 identical B-cell epitopes on 18 proteins of M. smegmatis
were recorded from the alignments.
From the prediction, 5 proteins are secreted, 8 proteins are
located in cytoplasm and 5 proteins locate in all of the cell
compartments of the bacteria.
It is interesting to note that all the 18 identified M. smegmatis
proteins containing the identical epitopes with M. tuberculosis
have assigned functions reported in the Reference Sequence
database at NCBI that correlate with the functions of the
13 M. tuberculosis identified target-proteins. This finding is
consistent with the close similarity between M. smegmatis
and M. tuberculosis at the genomic and functional levels.
This similarity is the bases of the use of M. smegmatis as a
model for the studies of the biology of M. tuberculosis and
for the development of drugs against tuberculosis.
Regarding the proteins of M. tuberculosis containing common
epitopes with M. smegmatis, the distribution according to the
functional categories of the 13 identified target-proteins is
shown in Figure 2. These 13 proteins mainly relate to the
intermediary metabolism and respiration; virulence,
detoxification, adaptation; lipid metabolism; cell wall and cell
processes; conserved hypothetical functions of tubercle
bacilli that were demonstrated highly expressed and
important for the bacteria to adapt to different host conditions
during different stages of infection (11, 12, 16-19, 21, 22).
Figure 1. A Venn diagram of the subcellular distribution of 38 identified
proteins of M. tuberculosis.
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Figure 2. Classification of M. tuberculosis proteins according to functional categories. The distribution according to functional categories of
the selected 38 highly expressed genes in vivo and of the subgroup of these genes sharing identical epitopes with proteins of M. smegmatis
(13 target-proteins) is shown. The distribution of genes of M. tuberculosis whole genome is shown as reference.
Evaluation of the immunogenicity of M. smegmatis
and the cross-reactivity with M. tuberculosis on
immunized mice
In vivo studies to evaluate the immunogenicity and the cross-
reactivity of two vaccine candidates from M. smegmatis:
proteoliposomes (PL) and live cells were carried out by an
indirect ELISA to determine the recognition M. smegmatis
and M. tuberculosis antigens by IgG antibodies of mice
immunized with these two experimental vaccines. The results
are shown in Figure 3.
Regarding the immunogenicity study, there was a statistical
increase of the specific antibodies in the group of mice
immunized with PL of M. smegmatis against whole cells of
M. smegmatis and whole cell lysate of M. tuberculosis
compared with the other groups (Figure 3). In the case of the
responses against PL of M. smegmatis, animals immunized
with PL had statistical increases of antibodies compared with
the negative control group (mice immunized with PBS) (Figure
3). These results showed a better immunogenicity of PL with
the adjuvant and immunization schedule used.
In the case of mice immunized with live cells of M. smegmatis,
there were not statistically significant differences with negative
control group against all the antigens tested. In this case,
whole cells or PL of M. smegmatis and whole cell lysate of
M. tuberculosis were not recognized by the antibodies of mice
immunized with live cells of M. smegmatis. It should be taken
into account that only one dose of immunization was used (as
usually used of BCG vaccination). In a study using M. smegmatis
as carrier vector for the expression of HIV proteins a more intensive
immunization schedule was used with repeated immunizations in
consecutive days (4).
Discussion
The expression of different genes during in vivo infection is
very important for the rational design of vaccines, considering
that only antigens expressed in vivo will have an effective
interaction with the immune system and enable to elicit
protective immune responses, so the study of this group of
antigens should have the priority for the identification of
relevant antigens/epitopes to be included in new vaccines.
One of the main objectives of this study was to identify
M. tuberculosis genes that are highly expressed in vivo in
order to establish a pre-selected pool of antigens for the
search of potential protective epitopes. In our case, we
searched for genes expressed in vivo in humans and animals
and in all phases of infection.
This is important in all strategies considering the need to
have the correlation between the animal model and human,
and on the other hand to have the inclusion of epitopes able
to be operative in all the stages of the infection where
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Figure 3.  Study of the immunogenicity and cross-reactivity in mice of two vaccine candidates from M. smegmatis. Serum samples of three
groups of mice immunized with PBS (negative control), proteoliposomes (PL) of M. smegmatis and M. smegmatis live cells (n=5 for each
group) were collected 42 days after the first injection and analyzed by ELISA for the presence of specific IgG antibodies against: M. smegmatis
whole cells [A], PL of M. smegmatis [B] and whole cell lysate (WCL) of M. tuberculosis [C]. Data are plotted as the mean of optical density (OD)
measurement at 492 nm. (*) denotes a statistically significant difference between PL vs. all groups, (**) denotes a statistically significant
difference between PL vs. PBS.
vaccination could be used (primary infection, latency and
clinical infection).
The distribution of the 38 highly expressed genes found in
this study is relevant for the development of vaccine
candidates targeting these antigens because they represent
proteins of high importance for the survival of the bacteria
during different phases of infection. Consequently, the
immune responses elicited against these proteins should
have a detrimental effect upon the bacteria, thus contributing
to the protection. On the other side, the high representation
of the cell wall component proteins gives the opportunity to
stimulate specific humoral immune responses. In this respect,
the potential of humoral antibodies in the protection against
mycobacterial infections was demonstrated (31).
The potential advantages of M. smegmatis as carrier or
experimental vaccine against tuberculosis is related to the
fact that it is rapidly destroyed by phagolysosomal proteases
in the phagosomes of infected cells (32-34), which is different
in other mycobacterial strains such as BCG that survive in
host cells for months by inhibiting phagosome maturation.
Nevertheless, M. smegmatis can induce cytokine production
by macrophages better than pathogenic mycobacterial
species and can activate and induce the maturation of
dendritic cells better than BCG by upregulation of major
histocompatibility complex (MHC) class I and costimulatory
molecules. M. smegmatis can also access the MHC class I
pathway for presentation of mycobacterial antigens more
efficiently than BCG (4).
The recognition of M. tuberculosis whole cell lysate by
animals immunized with PL of M. smegmatis demonstrated
the humoral cross-reactivity between M. smegmatis and
M. tuberculosis which matches the results obtained by in
silico studies where five identical B-cell epitopes were
identified from secreted, cell wall and membrane proteins
of M. smegmatis compared with M. tuberculosis.
It should be considered that, in addition to the linear
epitopes identified by the prediction algorithm, there could
be identical conformational B-cell epitopes between
M. smegmatis and M. tuberculosis reinforcing the humoral
cross-reactivity. Beside, we could detect the humoral
reactivity against lipid and carbohydrate components that
are present in the vaccine candidates used in this study
and in the different preparations used for the coating of
the ELISA systems (PL, whole M. smegmatis and whole
cell lysate of M. tuberculosis). In recent studies carried
out in our laboratory (29) and in collaboration with NIBSC,
UK (unpublished results) we demonstrated the humoral
immunogenicity of mycobacterial lipidic components in
humans. In the case of M. smegmatis it was revealed by
the cryo-electron microscope that the outermost layer of
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M. smegmatis is an outer membrane with a bilayer structure
of lipids (30). These components could be recognized by
the humoral immune responses.
In the in vivo study, it was only studied the humoral cross-
reactivity between M. smegmatis and M. tuberculosis, so it
could not be ruled out the presence of cross-reactivity at
cellular level after the immunization with the M. smegmatis
vaccine candidates, a fact that should be explored in future
studies taking into account the relevant role assigned to the
cellular immune response in the protection against
tuberculosis.
Studies carried out in our laboratory have demonstrated the
recognition of proteins of M. smegmatis by IgG antibodies
from pulmonary tuberculosis patients in a whole cell ELISA
assay. In those studies the levels of specific antibodies in
tuberculosis patients had a statistical increase compared with
healthy controls (unpublished results). The result
demonstrated that during in-vivo infection in humans
M. tuberculosis expresses epitopes present in M. smegmatis,
which matches the in silico and in vivo results obtained in
current study, in addition it supports the idea of the potential
use of M. smegmatis for the development of TB vaccine
candidates.
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Evaluación del potencial de Mycobacterium smegmatis como candidato vacunal
contra la tuberculosis mediante estudios in sílico e in vivo
Resumen
En este estudio se revisaron múltiples bases de datos publicadas, relacionadas con experimentos de expresión
de genes de M. tuberculosis in vivo en diferentes estadios de la infeccción en humanos y animales. Se identificaron
38 proteínas con elevada expresión en las fases activa, latente y de reactivación de la infección. Se llevó a cabo
la predicción de epítopes T y B en dichas proteínas. Las regiones de cada proteína que contenían simultáneamente
epítopes T y B se seleccionaron y utilizaron para identificar regiones idénticas en M. smegmatis mediante el
alineamiento de secuencias. Se llevaron a cabo estudios de inmunogenicidad humoral y reactividad cruzada
con M. tuberculosis en ratones inmunizados con dos vacunas experimentales obtenidas a partir de M. smegmatis,
demostrándose la immunogenicidad de los proteoliposomas y el reconocimiento de proteínas de M. tuberculosis
por el suero de ratones vacunados con este candidato vacunal. Los resultados obtenidos con los estudios in
sílico e in vivo sugieren la potencialidad para evaluación futura de candidatos vacunales obtenidos a partir de
M. smegmatis para la prevención de la tuberculosis.
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